Group 1: Core Views - The article highlights the recent surge in A-share market, particularly the significant rise of Hengyun Chang, which saw a peak increase of over 320% on its debut, yielding nearly 150,000 yuan per share [1][6] - This week, two new stocks are available for subscription: Yisiwei and Aide Technology, with Yisiwei being a leader in automotive manufacturing machine vision equipment and Aide Technology focusing on orthopedic medical devices [1][4] Group 2: Yisiwei Overview - Yisiwei's offering price is set at 55.95 yuan per share, with a maximum subscription limit of 6,000 shares per account, requiring a market value of 60,000 yuan in the Shanghai market for full subscription [1] - The company has developed over ten products for various automotive manufacturing processes, achieving a market share of 22.5% in China's automotive machine vision sector by 2024, surpassing foreign competitors [2] - Yisiwei's revenue projections for 2022 to 2024 are 223 million yuan, 355 million yuan, and 392 million yuan, respectively, with net profits of 6.12 million yuan, 61.06 million yuan, and 85.64 million yuan [2] Group 3: Aide Technology Overview - Aide Technology's offering price is 7.67 yuan per share, with a maximum subscription limit of 1.3288 million shares [4] - The company specializes in orthopedic medical devices, focusing on a comprehensive range of products for spinal, trauma, and sports medicine, and has developed several core technologies [4] - Revenue forecasts for Aide Technology from 2022 to 2024 are 286 million yuan, 262 million yuan, and 275 million yuan, with net profits of 93 million yuan, 64 million yuan, and 67 million yuan [4]

New IPOs This Week - Two new stocks are scheduled for subscription this week: Yisiwei (688816) and Aide Technology (920180) [1][3] - Yisiwei is a leader in automotive manufacturing machine vision equipment and plays a significant role in the localization process of this field in China [1][5] - Aide Technology focuses on the research, production, and sales of orthopedic medical devices, primarily orthopedic consumables [6][7] Company Overview: Yisiwei - Established in 2017, Yisiwei has developed over ten products that are applied across six major manufacturing processes: stamping, welding, painting, assembly, battery, and die-casting [1][5] - The company has achieved a competitive advantage by offering a comprehensive range of products and significantly reducing the costs of machine vision equipment for the domestic automotive industry [5] - Yisiwei has established partnerships with over 80% of domestic passenger car manufacturers [1][5] Company Overview: Aide Technology - Aide Technology has been in the orthopedic medical device industry for over ten years, focusing on clinical needs and developing a comprehensive product matrix covering various orthopedic fields [6][7] - The company initially specialized in spinal minimally invasive intervention and has expanded its offerings to include products for trauma, sports medicine, and wound healing [7] - Aide Technology aims to become a leading provider of comprehensive orthopedic surgical solutions in China [6][7] Market Position and Financials - Yisiwei's revenue scale is below the average of comparable companies, which is projected to be 1.573 billion yuan for 2024, with an average gross margin of 49.11% [5] - Aide Technology's revenue and gross margin are also below the average of its comparable companies, which have an average revenue of 1.166 billion yuan and a gross margin of 64.61% [7]

Investment Rating - The investment rating for the company is "Buy" with an expected relative increase of over 15% in the next 6-12 months compared to the relevant market index [40]. Core Insights - The company, Aide Technology (920180.BJ), primarily engages in the research, production, and sales of orthopedic medical devices, focusing on spinal, trauma, and sports medicine products, as well as wound healing products [6][8]. - The company has a strong market position in the orthopedic field, particularly in the spinal segment, with a market share of 1.29% in 2023, ranking sixth among domestic companies in the spinal implant market [33]. - Revenue projections for 2023-2025 are 262 million, 275 million, and 302 million yuan respectively, with year-over-year growth rates of -8.22%, 4.87%, and 9.74% [8][3]. - The company has launched new products in the hip and knee joint categories, expanding its product line and aiming for steady revenue growth [34]. Summary by Sections Basic Financial Status - The company achieved revenues of 262.1 million yuan in 2023, with a net profit of 63.6 million yuan, reflecting a year-over-year decline of 31.85% [3][8]. - The revenue for 2024 is projected to be 274.9 million yuan, with a slight recovery in net profit to 67.1 million yuan, indicating a growth of 5.60% [3][8]. Industry Situation - The orthopedic medical device industry is experiencing growth, driven by an aging population and increasing healthcare spending, with the market size expected to grow from 193 billion yuan in 2016 to 246 billion yuan by 2024 [16][17]. - The spinal implant market specifically is projected to recover in 2024, with a market size of 72 billion yuan, following a decline due to national procurement policies [18]. Company Highlights - Aide Technology has developed a comprehensive product matrix covering all areas of orthopedics, with 132 product registrations and a focus on the lower-tier medical market [33][34]. - The company has established a nationwide sales network, collaborating with over 3,000 hospitals across 31 provinces and municipalities [33]. Fundraising Project Investment - The company plans to invest in three main projects through its IPO: an orthopedic consumables expansion project, a research and development center, and a marketing network enhancement project [35][36]. Comparison with Peers - Compared to peer companies like Weigao Orthopedics and Dabo Medical, Aide Technology's revenue and gross margin are below the average, with a projected revenue of 2.75 billion yuan for 2024 [37][38].

Group 1: New Stock Offerings - Two new stocks are available for subscription on February 2, including Yisiwei on the Sci-Tech Innovation Board and Aide Technology on the Beijing Stock Exchange [2] - Aide Technology's total issuance, online issuance, and subscription limit rank first among new stocks on the Beijing Stock Exchange since 2026, with a subscription limit of 1.3288 million shares [2][3] - The total issuance of Aide Technology is 29.53 million shares, with 26.58 million shares available for online subscription [4] Group 2: Aide Technology Overview - Aide Technology is a leading company in the domestic medical device sector, focusing on orthopedic consumables, including spinal, trauma, and sports medicine products [4][6] - The company ranks third in the domestic market for spinal vertebral body augmentation systems and sixth for spinal implant medical devices [6] - Aide Technology's revenue for 2022 to 2025 is projected to be 286 million, 262 million, 275 million, and 149 million yuan, respectively, with net profits of approximately 93.28 million, 63.57 million, 67.13 million, and 38.15 million yuan [8][9] Group 3: Yisiwei Overview - Yisiwei is a leading company in the domestic machine vision sector, focusing on the development, production, and sales of machine vision equipment for automotive manufacturing [10][11] - The total issuance of Yisiwei is 25 million shares, with 6 million shares available for online subscription and a subscription limit of 600 shares [11] - Yisiwei's revenue for 2022 to 2025 is projected to be 223 million, 355 million, 392 million, and 125 million yuan, respectively, with net profits of approximately 6.12 million, 61.06 million, 85.64 million, and a loss of 509,910 yuan [13][14]

Core Viewpoint - The orthopedic consumables industry in China has shown signs of recovery after three years of collective procurement, with leading domestic companies reporting significant revenue and profit growth in Q3 2025, particularly driven by overseas market expansion [1][2]. Group 1: Company Performance - Major domestic orthopedic companies have reported strong financial results for Q3 2025, with many achieving both revenue and net profit growth, indicating a positive trend in the industry [1]. - Companies like Chuangli Medical, Dabo Medical, and Weigao Orthopedics have seen substantial stock price increases, with Chuangli Medical's stock rising over 90% year-to-date as of November 25 [1]. - Aikang Medical, despite being one of the first to recover from the procurement downturn, has lagged behind with a year-to-date stock increase of only 17.23% and faces risks of being removed from the Hong Kong Stock Connect list [1]. Group 2: Market Trends - The orthopedic consumables market is expected to grow significantly, with projections indicating a rise to $62.22 billion in 2024 and over $94 billion by 2032, reflecting a stable annual growth rate of 5.3% [3]. - Companies are increasingly focusing on overseas market expansion as a critical growth strategy, especially as the domestic market becomes saturated due to collective procurement [3][4]. Group 3: Stock Performance Analysis - Aikang Medical's stock experienced a steady rise in the first half of the year, reaching a peak of 7.24 HKD on July 30, with a cumulative increase of 53.72% [2]. - However, following the release of its mid-year performance, Aikang's stock fell sharply, indicating market volatility and investor sentiment not aligning with its revenue growth [2][3]. - The stock has been in a low volatility phase since mid-year, with a minimal price increase of 0.36% from August 29 to November 25, despite significant price fluctuations [7]. Group 4: Investment Considerations - Aikang Medical's average market capitalization during the review period is 6.349 billion HKD, slightly above the threshold for inclusion in the Hong Kong Stock Connect, necessitating stable market performance to avoid exclusion [11]. - The stock's current PE ratio has dropped to 19.51, below the industry average, suggesting potential for investment as the orthopedic consumables market continues to recover [14].

Investment Rating - The report gives a "Buy" rating for Sanyou Medical (688085.SH) [1] Core Views - Sanyou Medical is a leading enterprise in the orthopedic field, focusing on innovation to drive growth. The company has established a strong market position in spinal implant consumables and is expanding its product offerings and international presence [6][7][11]. - The orthopedic implant consumables industry is expected to return to a stable growth phase post-volume-based procurement, driven by increasing demand due to an aging population and rising healthcare awareness [27][30]. - The company is actively pursuing internationalization and has made strategic acquisitions to enhance its product portfolio and market reach [7][41]. Summary by Sections 1. Leading Enterprise in Orthopedics, Driven by Innovation - Sanyou Medical has been dedicated to the orthopedic industry since its establishment in 2005, focusing on the research, production, and sales of orthopedic implant consumables. The company has built a strong brand reputation and market position in spinal implants [6][11]. - The company has faced challenges due to volume-based procurement but has leveraged its innovation and quality to maintain and grow its market share [11][23]. 2. Post-Procurement Era, Orthopedic Industry Expected to Maintain Steady Growth - The orthopedic implant consumables market is projected to rebound to stable growth, with a market size expected to reach 269 billion yuan in 2024, reflecting a year-on-year increase of 13.5% [30][33]. - The demand for orthopedic products is anticipated to rise due to the aging population and increased healthcare spending [30][32]. 3. Continuous Innovation to Open Growth Opportunities - Sanyou Medical is committed to therapy innovation, enhancing its product offerings, and expanding into new market segments, including ultrasound bone knives and orthopedic robots [6][41]. - The company has made significant investments in R&D, resulting in the successful launch of new products that address clinical needs and improve surgical outcomes [17][44]. 4. Commitment to Internationalization and Market Expansion - The company has acquired the French orthopedic company Implanet to strengthen its international presence and leverage existing sales channels in Europe and the U.S. [7][41]. - Sanyou Medical aims to build a robust overseas marketing network, focusing on high-end markets with innovative product offerings [7][41]. 5. Profit Forecast and Valuation - The report forecasts Sanyou Medical's net profit to reach 87 million yuan in 2025, 160 million yuan in 2026, and 257 million yuan in 2027, indicating strong growth potential [5][7].

Core Viewpoint - Zimmer Biomet demonstrates robust growth and improved profitability in its Q2 2025 financial results, with a net sales increase of 7.0% year-over-year, reaching $2.077 billion, and a Non-GAAP EPS of $2.07, exceeding market expectations [2][4]. Financial Performance - The company reported net sales of $2.077 billion in Q2 2025, up from $1.942 billion in Q2 2024, reflecting a 7.0% increase [3]. - Operating profit decreased to $300 million from $351.3 million year-over-year, while net earnings fell to $152.8 million from $242.8 million [3][4]. - The adjusted EPS guidance for the full year was raised from $7.90–8.10 to $8.10–8.30, indicating management's confidence in the second half of 2025 [2]. Growth Drivers - The S.E.T. (Sports Medicine, Extremities, Trauma) segment showed significant growth, with revenues reaching $550.6 million, a 17.3% increase year-over-year, driven by rapid integration and product iteration in the ankle business [5][7]. - The company launched new products in the hip joint sector, such as the Z1 Hip Stem, which have gained initial success in the North American market [7]. Digital Transformation - Zimmer Biomet is accelerating its digital transformation with the ZBEdge platform, which integrates hardware, software, and data [8]. - The ROSA surgical robot system has been updated to enhance intraoperative verification and imaging fusion capabilities [10]. - The acquisition of Monogram Technologies aims to improve personalized preoperative planning and intraoperative execution capabilities [12]. Management Outlook - The CEO emphasized a shift from being a "device giant" to a "technology platform company," focusing on digital orthopedics, surgical robotics, and remote rehabilitation management [13]. - The management anticipates that orthopedic business revenue will decline to below 50% of total revenue by 2025, with digital and high-value consumables becoming new growth engines [13]. Challenges and Strategic Transition - Despite strong performance, the company faces short-term integration costs and external variables such as tariffs and logistics costs [14]. - The transition from "procedure replacement" to "full-process empowerment" is underway, with new product cycles and multi-platform interactions laying the foundation for the next decade of growth [14]. Company Overview - Zimmer Biomet is a leading medical technology company focused on innovative products and digital solutions in orthopedics, neuroscience, spine, and cranio-maxillofacial reconstruction [15]. - The company is headquartered in Warsaw, Indiana, and operates in over 100 countries, aiming to enhance the quality of life for patients through technology and surgical advancements [15].

Core Viewpoint - Enovis Corporation has launched the Manafuse® bone growth stimulator, a portable device utilizing low-intensity pulsed ultrasound (LIPUS) technology for non-invasive treatment of fresh fractures and non-union fractures, aiming to accelerate healing processes [1][3][4]. Product Overview - Manafuse® stimulates the body's natural healing process by emitting LIPUS signals, designed for specific fresh fractures and non-union fractures, excluding cranial and vertebral bones [3][4]. - The device is portable, battery-operated, and requires only 20 minutes of daily use, with a maximum usage period of 343 days, making it suitable for home use [4]. - LIPUS technology has 30 years of clinical evidence supporting its effectiveness in improving fracture healing [4][7]. Clinical Data - A prospective, randomized, double-blind, placebo-controlled study indicated that LIPUS treatment can accelerate healing by 38%, with a difference of over 8 weeks [9]. - Clinical studies report a success rate of up to 86% for Manafuse in treating non-union fractures [9]. Market Overview - The global bone growth stimulator market is projected to grow from $1.4 billion in 2022 to $1.8 billion by 2027, with a compound annual growth rate (CAGR) of 5.9% [13]. - Key growth drivers include an increasing target patient population, rising sports and orthopedic-related injuries, and an aging population [13]. - Major competitors in the market include Orthofix Medical Inc., ZimVie, Bioventus LLC, Medtronic, Stryker, and DePuy Synthes [13]. Financial Performance - Enovis reported a loss of $703.3 million, with a net loss attributed to a non-cash goodwill impairment charge of $645 million related to its Recon and P&R business segments [22]. - Despite a 23.3% increase in sales to approximately $561 million, the company faced significant net losses [22]. - Adjusted earnings per share are expected to be between $3.10 and $3.25 for 2025, with sales projected between $2.19 billion and $2.22 billion [22].

为加强全球骨科医疗器械行业的交流合作，促进中国骨科医疗技术的创新发展，推动最新 科技在骨科领域的应用， 首届全球骨科大会（Global Orthopedics Conference 2025 ） 将 于 2025年4月24日在北京中关村展示中心 隆重举办 。 25+行业大咖将围绕骨科前沿展开巅峰对话 500+业内人士出席 尚有少量展位，欢迎联系微信号：suribot22 会议报名 ：复制以下链接到 IE 浏览器或点击文末 "阅读原文" 进行填写 https://hdxu.cn/125no 或扫描下方二维码进行填写 Global Orthopedics Conference 2025 一、活动时间： 2025年4月24日 星期四 二、活动地点： 北京市中关村自主创新示范区展示中心（海淀桥西北角） 三、举办单位： 骨未来｜智汇骨 | 思宇MedTech；中关村联新生物医药产业联盟、北京中关村科学城创新发展有限公司、北京中关村创业大街科技服务有限公司、 启迪之星 四、会议规模： 现场参会嘉宾500人 五、大会议程 9:00 - 9:10 致辞环节 9:10 - 9:15 《 2025全球骨科创新年度白皮书》发布 9 ...

为给予更多优秀骨科技术公司、医疗机构、骨科器械制造商及其他相关单位充分的时间准备和完善申报材料，主办方 骨未来 、 思宇 MedTech 现决定将 奖项评选报名截止时间延期至 2025年3月17日24:00 。 此次延期旨在为有意参选的各方提供更充裕的时间窗口，以便大家能够更全面、深入地 展示自身在骨科医疗器械领域的创新成果与卓越 贡献，分享前沿经验，推动骨科医疗技术的持续进步 。 请有意参选的单位务必在新的截止日期前，通过以下链接提交完整的申报资料 ： https://docs.qq.com/form/page/DUGJueWNLeXVQVExX 评奖通知： 奖项亮点： 成立8年的专业媒体"思宇MedTech"旗下"骨未来"+学术媒体"智汇骨"组织 ， 兼具权威性+影响力 全球宣传，美通社、美联社、路透社等同步报道； 国内主流传统媒体同步报道（覆盖科技日报、中国青年报、新华网、 健康报、北京日报等）； 获奖结果常驻骨未来文章底栏，每天曝光、长达一年；一对一推送骨未来&思宇MedTech覆盖的投资机构、合作医院、政 府机构等。 中关村展示中心会议中心 一、颁奖日期 如有任何疑问或需进一步协助，可随时联系骨未来 ...